Patient Acceptability and Preferences for Solid Oral Dosage Form Drug Product Attributes: A Scoping Review

References

• Stegemann S, Ternik RL, Onder G, Khan MA, van Riet-Nales DA. Defining patient centric pharmaceutical drug product design. AAPS J. 2016;18(5):1047–1055. doi:10.1208/s12248-016-9938-6
   PubMed Web of Science ®Google Scholar
• Algorri M, Cauchon NS, Christian T, O’Connell C, Vaidya P. Patient-centric product development: a summary of select regulatory CMC and device considerations. J Pharm Sci. 2023;112(4):922–936. doi:10.1016/j.xphs.2023.01.029
   PubMed Web of Science ®Google Scholar
• Menditto E, Orlando V, De Rosa G, et al. Patient centric pharmaceutical drug product design-the impact on medication adherence. Pharmaceutics. 2020;12(1):44. doi:10.3390/pharmaceutics12010044
   PubMed Web of Science ®Google Scholar
• Stegemann S. Patient centric drug product design in modern drug delivery as an opportunity to increase safety and effectiveness. Expert Opin Drug Deliv. 2018;15(6):619–627. doi:10.1080/17425247.2018.1472571
   PubMed Web of Science ®Google Scholar
• Timpe C, Stegemann S, Barrett A, Mujumdar S. Challenges and opportunities to include patient-centric product design in industrial medicines development to improve therapeutic goals. Br J Clin Pharmacol. 2020;86(10):2020–2027. doi:10.1111/bcp.14388
   PubMed Web of Science ®Google Scholar
• Drumond N. Future perspectives for patient-centric pharmaceutical drug product design with regard to solid oral dosage forms. J Pharm Innov. 2020;15(3):318–324. doi:10.1007/s12247-019-09407-2
   Web of Science ®Google Scholar
• Smith MY, Janssens R, Jimenez-Moreno AC, et al. Patients as research partners in preference studies: learnings from IMI-PREFER. Res Involv Engagem. 2023;9(1):21. doi:10.1186/s40900-023-00430-9
   PubMedGoogle Scholar
• Cook NS, Cave J, Holtorf AP. Patient preference studies during early drug development: aligning stakeholders to ensure development plans meet patient needs. Front Med Lausanne. 2019;6:82. doi:10.3389/fmed.2019.00082
   PubMed Web of Science ®Google Scholar
• Liu F, Ranmal S, Batchelor HK, et al. Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations. Drugs. 2014;74(16):1871–1889. doi:10.1007/s40265-014-0297-2
   PubMed Web of Science ®Google Scholar
• Drumond N, Stegemann S. Better medicines for older patients: considerations between patient characteristics and solid oral dosage form designs to improve swallowing experience. Pharmaceutics. 2020;13(1):32. doi:10.3390/pharmaceutics13010032
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on pharmaceutical development of medicines for paediatric use; 2013. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf. Accessed July 21, 2023.
   Google Scholar
• Kozarewicz P. Regulatory perspectives on acceptability testing of dosage forms in children. Int J Pharm. 2014;469(2):245–248. doi:10.1016/j.ijpharm.2014.03.057
   PubMed Web of Science ®Google Scholar
• Ternik R, Liu F, Bartlett JA, et al. Assessment of swallowability and palatability of oral dosage forms in children: report from an M-CERSI pediatric formulation workshop. Int J Pharm. 2018;536(2):570–581. doi:10.1016/j.ijpharm.2017.08.088
   PubMed Web of Science ®Google Scholar
• Hummler H, Stillhart C, Meilicke L, et al. Impact of tablet size and shape on the swallowability in older adults. Pharmaceutics. 2023;15(4):1042. doi:10.3390/pharmaceutics15041042
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Patient preference information – voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling. US Department of Health and Human Services; 2015. Available from: https://www.fda.gov/media/92593/download. Accessed October 6, 2023.
   Google Scholar
• European Medicines Agency. Note for guidance on pharmaceutical development; 2009. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-pharmaceutical-development_en.pdf. Accessed July 21, 2023.
   Google Scholar
• US Food and Drug Administration. Safety considerations for product design to minimize medication errors: guidance for industry. US Department of Health and Human Services; 2016. Available from: https://www.fda.gov/media/84903/download. Accessed September 8, 2023.
   Google Scholar
• US Food and Drug Administration. Size, shape, and other physical attributes of generic tablets and capsules. US Department of Health and Human Services; 2022. Available from: https://www.fda.gov/media/161902/download. Accessed May 31, 2024.
   Google Scholar
• National Institute for Health and Care Excellence. Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence; 2009. Available from: https://www.nice.org.uk/guidance/cg76/resources/medicines-adherence-involving-patients-in-decisions-about-prescribed-medicines-and-supporting-adherence-pdf-975631782085. Accessed July 21, 2023.
   Google Scholar
• Awad A, Trenfield SJ, Basit AW. Chapter 19 - Solid oral dosage forms. In: Adejare A, editor. Remington. Academic Press; 2021:333–358.
   Google Scholar
• Debotton N, Dahan A. Applications of polymers as pharmaceutical excipients in solid oral dosage forms. Med Res Rev. 2017;37(1):52–97. doi:10.1002/med.21403
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Size, shape, and other physical attributes of generic tablets and capsules. US Department of Health and Human Services; 2015. Available from: https://www.fda.gov/media/87344/download. Accessed May 31, 2024
   Google Scholar
• Stegemann S. Colored capsules-a contribution to drug safety. Pharmazeutische Industr. 2005;67(9):1088.
   Web of Science ®Google Scholar
• Branch E Oral solid dose and the psychology of appearance. Pharma’s Almanac. Available from: https://www.pharmasalmanac.com/articles/oral-solid-dose-and-the-psychology-of-appearance. Accessed September 7, 2023.
   Google Scholar
• De Craen AJ, Roos PJ, De Vries AL, Kleijnen J. Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. BMJ. 1996;313(7072):1624–1626. doi:10.1136/bmj.313.7072.1624
   PubMed Web of Science ®Google Scholar
• Spence C. The multisensory design of pharmaceuticals and their packaging. Food Qual Prefer. 2021;91:104200. doi:10.1016/j.foodqual.2021.104200
   Web of Science ®Google Scholar
• Tao D, Wang T, Wang T, Qu X. Influence of drug colour on perceived drug effects and efficacy. Ergonomics. 2018;61(2):284–294. doi:10.1080/00140139.2017.1349935
   PubMed Web of Science ®Google Scholar
• Alessandrini E, Gonakova M, Batchelor H, et al. Colour of medicines and children’s acceptability? A systematic literature review of children’s perceptions about colours of oral dosage forms. Pharmaceutics. 2023;15(7):1992. doi:10.3390/pharmaceutics15071992
   PubMed Web of Science ®Google Scholar
• Kurczewska-Michalak M, Kardas P, Czajkowski M. Patients’ preferences and willingness to pay for solid forms of oral medications—results of the discrete choice experiment in Polish outpatients. Pharmaceutics. 2020;12(3):236. doi:10.3390/pharmaceutics12030236
   PubMed Web of Science ®Google Scholar
• Shariff Z, Kirby D, Missaghi S, Rajabi-Siahboomi A, Maidment I. Patient-centric medicine design: key characteristics of oral solid dosage forms that improve adherence and acceptance in older people. Pharmaceutics. 2020;12(10):905. doi:10.3390/pharmaceutics12100905
   PubMed Web of Science ®Google Scholar
• Shariff ZB, Dahmash DT, Kirby DJ, Missaghi S, Rajabi-Siahboomi A, Maidment ID. Does the formulation of oral solid dosage forms affect acceptance and adherence in older patients? A mixed methods systematic review. J Am Med Dir Assoc. 2020;21(8):1015–1023.e8. doi:10.1016/j.jamda.2020.01.108
   PubMed Web of Science ®Google Scholar
• Venables R, Batchelor H, Hodson J, Stirling H, Marriott J. Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population. Int J Pharm. 2015;480(1):55–62. doi:10.1016/j.ijpharm.2015.01.023
   PubMedGoogle Scholar
• European Medicines Agency; 2022. Reflection paper on the pharmaceutical development of medicines for use in the older population. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-pharmaceutical-development-medicines-use-older-population-first-version_en.pdf. Accessed September 14, 2023.
   Google Scholar
• Peters MD, Godfrey CM, McInerney P, Soares CB, Khalil H, Parker D. The Joanna Briggs Institute Reviewers’ Manual 2015: Methodology for JBI Scoping Reviews. Joanna Briggs Institute; 2015.
   Google Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–473. doi:10.7326/M18-0850
   PubMed Web of Science ®Google Scholar
• Aromataris E, Munn Z JBI manual for evidence synthesis. Joanna Briggs Institute; 2020.
   Google Scholar
• Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. doi:10.1191/1478088706qp063oa
   Google Scholar
• Kaukonen AM Patient acceptability EMA regulatory considerations. Finnish Medicines Agency. 2016. Available from: https://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/cersievents/pedsformulation/kaukonen-presentation-notes.pdf. Accessed October 6, 2023.
   Google Scholar
• Helter TM, Boehler CE. Developing attributes for discrete choice experiments in health: a systematic literature review and case study of alcohol misuse interventions. J Subst Use. 2016;21(6):662–668. doi:10.3109/14659891.2015.1118563
   PubMed Web of Science ®Google Scholar
• Bracken L, McDonough E, Ashleigh S, et al. Can children swallow tablets? Outcome data from a feasibility study to assess the acceptability of different-sized placebo tablets in children (creating acceptable tablets (CAT)). BMJ Open. 2020;10(10):e036508. doi:10.1136/bmjopen-2019-036508
   PubMed Web of Science ®Google Scholar
• Bracken L, Habashy R, McDonough E, et al. Creating acceptable tablets 3D (CAT 3D): a feasibility study to evaluate the acceptability of 3D printed tablets in children and young people. Pharmaceutics. 2022;14(3):516. doi:10.3390/pharmaceutics14030516
   PubMed Web of Science ®Google Scholar
• Goyanes A, Scarpa M, Kamlow M, Gaisford S, Basit AW, Orlu M. Patient acceptability of 3D printed medicines. Int J Pharm. 2017;530(1):71–78. doi:10.1016/j.ijpharm.2017.07.064
   PubMed Web of Science ®Google Scholar
• Hofmanová JK, Mason J, Batchelor HK. Sensory aspects of acceptability of bitter-flavoured 7.5 mm film-coated tablets in adults, preschool and school children. Int J Pharm. 2020;585:119511. doi:10.1016/j.ijpharm.2020.119511
   PubMedGoogle Scholar
• Hofmanová JK, Rajabi-Siahboomi A, Haque S, et al. Developing methodology to evaluate the oral sensory features of pharmaceutical tablet coatings. Int J Pharm. 2019;562:212–217. doi:10.1016/j.ijpharm.2019.03.046
   PubMedGoogle Scholar
• Liu F, Ghaffur A, Bains J, Hamdy S. Acceptability of oral solid medicines in older adults with and without dysphagia: a nested pilot validation questionnaire based observational study. Int J Pharm. 2016;512(2):374–381. doi:10.1016/j.ijpharm.2016.03.007
   PubMed Web of Science ®Google Scholar
• Ranmal S, Tuleu C. Piloting the children’s acceptability of oral formulations (CALF) medicines survey to determine perceptions and practices with paediatrics medicines. Arch Dis Child. 2013;98(6):e1–e1. doi:10.1136/archdischild-2013-303935b.7
   PubMedGoogle Scholar
• Barenie RE, Kesselheim AS, Gagne JJ, et al. Preferences for and experiences with pill appearance changes: national surveys of patients and pharmacists. Am J Manag Care. 2020;26(8):340–347.
   PubMed Web of Science ®Google Scholar
• Osborn ZF, Acosta TJP, Lee JC, McNicholl I, McKinnon JE. Characterization of patient pill preferences from a prospective placebo vs. placebo ease of swallowability study. Open Forum Infect Dis. 2019;6(Suppl 2):S871–S872. doi:10.1093/ofid/ofz360.2189
   Google Scholar
• Fastø MM, Genina N, Kaae S, Kälvemark Sporrong S. Perceptions, preferences and acceptability of patient designed 3D printed medicine by polypharmacy patients: a pilot study. Int J Clin Pharm. 2019;41(5):1290–1298. doi:10.1007/s11096-019-00892-6
   PubMed Web of Science ®Google Scholar
• Vallet T, Michelon H, Orlu M, et al. Acceptability in the older population: the importance of an appropriate tablet size. Pharmaceutics. 2020;12(8):746. doi:10.3390/pharmaceutics12080746
   PubMed Web of Science ®Google Scholar
• Kabeya K, Satoh H, Hori S, Sawada Y. Experimental study on patient preferences regarding the shape and size of medical tablets and capsules using three-dimensionally printed plastic model formulations. Patient Prefer Adher. 2021;Volume 15:863–870. doi:10.2147/PPA.S306582
   Web of Science ®Google Scholar
• Almukainzi M. Assessment of oral solid dosage forms administration manner and acceptability. Pharmacia. 2021;68(2):393–400. doi:10.3897/pharmacia.68.e65604
   Web of Science ®Google Scholar
• Wargenau M, Reidemeister S, Klingmann I, Klingmann V. A composite endpoint for acceptability evaluation of oral drug formulations in the pediatric population. Ther Innov Regul Sci. 2022;56(6):903–909. doi:10.1007/s43441-022-00406-z
   PubMed Web of Science ®Google Scholar
• MacKenzie-Smith L, Marchi P, Thorne H, Timeus S, Young R, Le Calvé P. Patient preference and physician perceptions of patient preference for oral pharmaceutical formulations: results from a real-life survey. Inflamm Intest Dis. 2018;3(1):43–51. doi:10.1159/000493346
   PubMedGoogle Scholar
• Wallace KL, Middleton S, Cook IJ. Development and validation of a self-report symptom inventory to assess the severity of oral-pharyngeal dysphagia. Gastroenterology. 2000;118(4):678–687. doi:10.1016/S0016-5085(00)70137-5
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Use of liquids and/or soft foods as vehicles for drug administration: General considerations for selection and in vitro methods for product quality assessments. U.S. Department of Health and Human Services; 2018. Available from: https://www.fda.gov/media/114872/download. Accessed September 13, 2023.
   Google Scholar
• European Medicines Agency. Pharmaceutical form. Available from: https://www.ema.europa.eu/en/glossary/pharmaceutical-form. Accessed September 15, 2023.
   Google Scholar
• Robertson WO. Drug-imprint coding. JAMA. 1974;229(7):766. doi:10.1001/jama.1974.03230450016010
   PubMed Web of Science ®Google Scholar
• Stewart KD, Johnston JA, Matza LS, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adher. 2016;10:1385–1399. doi:10.2147/PPA.S101821
   PubMed Web of Science ®Google Scholar
• McGrady ME, Pai ALH. A systematic review of rates, outcomes, and predictors of medication non-adherence among adolescents and young adults with cancer. J Adolesc Young Adult Oncol. 2019;8(5):485–494. doi:10.1089/jayao.2018.0160
   PubMed Web of Science ®Google Scholar
• Gil-Guillen VF, Balsa A, Bernárdez B, et al. Medication non-adherence in rheumatology, oncology and cardiology: a review of the literature of risk factors and potential interventions. Int J Environ Res Public Health. 2022;19(19):12036. doi:10.3390/ijerph191912036
   PubMed Web of Science ®Google Scholar
• Losi S, Berra CCF, Fornengo R, Pitocco D, Biricolti G, Federici MO. The role of patient preferences in adherence to treatment in chronic disease: a narrative review. Drug Target Insights. 2021;15:13. doi:10.33393/dti.2021.2342
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Letter of support for an acceptability score test in relative acceptability testing for oral medicines in children under 12 years of age. 2023. Available from: https://www.ema.europa.eu/en/documents/other/letter-support-acceptability-score-test-relative-acceptability-testing-oral-medicines-children-under_en.pdf. Accessed July 21, 2023.
   Google Scholar
• Avila-Sierra A, Lavoisier A, Timpe C, et al. Paediatric solid oral dosage forms for combination products: improving in vitro swallowability of minitablets using binary mixtures with pellets. Eur J Pharm Sci. 2023;187:106471. doi:10.1016/j.ejps.2023.106471
   PubMed Web of Science ®Google Scholar
• Burke MD, Keeney M, Kleinberg R, Burlage R. Challenges and opportunities for patient centric drug product design: industry perspectives. Pharm Res. 2019;36(6):85. doi:10.1007/s11095-019-2616-5
   PubMed Web of Science ®Google Scholar
• Stegemann S, Sheehan L, Rossi A, et al. Rational and practical considerations to guide a target product profile for patient-centric drug product development with measurable patient outcomes – a proposed roadmap. Eur J Pharmaceut Biopharm. 2022;177:81–88. doi:10.1016/j.ejpb.2022.06.006
   PubMed Web of Science ®Google Scholar
• McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012;22(3):276–282. doi:10.11613/BM.2012.031
   PubMed Web of Science ®Google Scholar
• Pollock D, Tricco AC, Peters MDJ, et al. Methodological quality, guidance, and tools in scoping reviews: a scoping review protocol. JBI Evid Synth. 2022;20(4):1098–1105. doi:10.11124/JBIES-20-00570
   PubMedGoogle Scholar
• Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143. doi:10.1186/s12874-018-0611-x
   PubMed Web of Science ®Google Scholar